Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent.
Publication/Presentation Date
12-1-2021
Abstract
BACKGROUND: Cardiac sarcoidosis (CS) is a major cause of morbidity and mortality in patients with systemic sarcoidosis. Steroid-sparing agents are increasingly used, despite a lack of randomized trials or published guidelines to direct treatment.
METHODS AND RESULTS: This retrospective study included 77 patients with CS treated with prednisone monotherapy (n = 32) or a combination with mycophenolate mofetil (n = 45) between 2003 and 2018. Baseline characteristics and clinical outcomes were evaluated. The mean patient age was 53 ± 11 years at CS diagnosis, 66.2% were male, and 35.1% were Black. The total exposure to maximum prednisone dose (initial prednisone dose × days at dose) was lower in the combination therapy group (1440 mg [interquartile range (IQR), 1200-2760 mg] vs 2710 mg [IQR, 1200-5080 mg]; P = .06). On
CONCLUSIONS: Mycophenolate mofetil in combination with prednisone for the treatment of CS may minimize corticosteroid exposure and decrease cardiac inflammation without significant adverse effects.
Volume
27
Issue
12
First Page
1348
Last Page
1358
ISSN
1532-8414
Published In/Presented At
Griffin, J. M., Chasler, J., Wand, A. L., Okada, D. R., Smith, J. N., Saad, E., Tandri, H., Chrispin, J., Sharp, M., Kasper, E. K., Chen, E. S., & Gilotra, N. A. (2021). Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent. Journal of cardiac failure, 27(12), 1348–1358. https://doi.org/10.1016/j.cardfail.2021.06.010
Disciplines
Medicine and Health Sciences
PubMedID
34166800
Department(s)
Department of Medicine, Cardiology Division
Document Type
Article